Celecoxib vs tNSAIDs
Celecoxib showed no clear difference in number withdrawn due to adverse events compared with tNSAIDs (low certainty).
- Peto OR 0.97 [0.74, 1.27]8 studies · 3150 participantsLow
Ranked among the 5,000 newest matching findings; add words or filters to narrow the search.
Celecoxib showed no clear difference in number withdrawn due to adverse events compared with tNSAIDs (low certainty).
Celecoxib showed no clear difference in number withdrawn due to adverse events compared with placebo (moderate certainty).
Epoetin alpha every 2 weeks showed no clear difference in adverse events: thrombovascular events compared with to weekly (low certainty).
The review found no eligible studies for this question.
LAMAs showed no clear difference in adverse events after tiotropium 5.0 µg compared with placebo (high certainty).
Active cancer therapy combined with TCM probably leads to lower adverse events ‐ arrest of bone marrow compared with active cancer therapy (moderate certainty).
Specific allergen immunotherapy showed no clear difference in adverse events ‐ any systemic reaction compared with no immunotherapy (moderate certainty).
Any antibiotic treatment may leads to higher minor adverse events in sexual partner compared with placebo (low certainty).
Paracetamol showed no clear difference in serious adverse events Up to 12 weeks' compared with placebo (moderate certainty).
The intervention leads to higher discontinuations due to adverse events (high certainty).
It is very uncertain whether methotrexate + infliximab changes serious adverse events (Schröder 2006) compared with infliximab alone (very low certainty).
The review found no eligible studies for this question.
Summary of findings table ‐ Concizumab prophylaxis showed no clear difference in adverse events ‐ Serious adverse events compared with on‐demand therapy (low certainty).
Summary of findings table ‐ Fitusiran prophylaxis showed no clear difference in adverse events ‐ Serious adverse events compared with on‐demand therapy (moderate certainty).
It is very uncertain whether prostaglandin changes adverse events considered non‐serious ( compared with placebo or standard care (very low certainty).
It is very uncertain whether hyaluronic acid changes adverse events ‐ incidence of infection compared with neutral vehicle (very low certainty).